Veracyte (VCYT) Projected to Post Quarterly Earnings on Thursday

Veracyte (NASDAQ:VCYT) is expected to announce its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect Veracyte to post earnings of $0.44 per share and revenue of $144.5950 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Veracyte (NASDAQ:VCYT) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.18. Veracyte had a net margin of 16.25% and a return on equity of 9.07%. The firm had revenue of $139.07 million for the quarter, compared to analysts’ expectations of $130.36 million. During the same period in the prior year, the company posted $0.31 earnings per share. The firm’s quarterly revenue was up 21.5% on a year-over-year basis. On average, analysts expect Veracyte to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Veracyte Price Performance

NASDAQ VCYT opened at $55.65 on Wednesday. The company has a market capitalization of $4.44 billion, a price-to-earnings ratio of 51.06 and a beta of 1.93. Veracyte has a 12 month low of $22.92 and a 12 month high of $60.91. The company’s fifty day moving average price is $53.19 and its two-hundred day moving average price is $42.08.

Insider Activity

In other news, Director Karin Eastham sold 3,729 shares of the firm’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $52.89, for a total value of $197,226.81. Following the transaction, the director directly owned 15,097 shares in the company, valued at approximately $798,480.33. This trade represents a 19.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John Leite sold 13,975 shares of Veracyte stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $50.07, for a total transaction of $699,728.25. Following the completion of the transaction, the insider directly owned 132,305 shares of the company’s stock, valued at $6,624,511.35. This trade represents a 9.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 206,696 shares of company stock valued at $10,079,058 over the last quarter. 1.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Veracyte

Several institutional investors and hedge funds have recently bought and sold shares of VCYT. CIBC Private Wealth Group LLC grew its holdings in shares of Veracyte by 599.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 6,195 shares of the biotechnology company’s stock valued at $261,000 after purchasing an additional 5,309 shares during the last quarter. Systematic Alpha Investments LLC acquired a new position in Veracyte during the 4th quarter valued at approximately $240,000. Bank of Montreal Can acquired a new position in Veracyte during the 4th quarter valued at approximately $226,000. Cibc World Markets Corp bought a new position in Veracyte during the 4th quarter worth $218,000. Finally, Neuberger Berman Group LLC acquired a new stake in Veracyte in the fourth quarter worth $213,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on VCYT shares. Jefferies Financial Group assumed coverage on shares of Veracyte in a research note on Monday, April 13th. They issued a “buy” rating and a $45.00 target price on the stock. Canaccord Genuity Group lifted their price target on Veracyte from $42.00 to $60.00 and gave the stock a “hold” rating in a research note on Tuesday, July 14th. UBS Group boosted their price objective on Veracyte from $48.00 to $52.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Zacks Research cut Veracyte from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Guggenheim upped their price objective on Veracyte from $45.00 to $65.00 and gave the company a “buy” rating in a research note on Monday, June 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.88.

About Veracyte

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.